NCT02183324已完成2 期
A Randomised, Double-blind, Placebo-controlled, Multiple Dose Phase II Study of BI 1356 BS (0.5 mg, 2.5 mg, and 10 mg in Tablet q.d. Administered Orally for 28 Days) to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Japanese Patients With Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 72
- 主要终点
- Number of patients with adverse events
研究概览
简要总结
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS (0.5 mg, 2.5 mg, and 10 mg) administered orally once daily for 28 days in Japanese patients with type 2 diabetes mellitus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Japanese patients with a diagnosis of type 2 diabetes mellitus treated with diet and/or exercise only or with one or two oral hypoglycaemic agents except glitazones
- •Glycosylated haemoglobin A1 (HbA1c)
- •<= 8.5% at screening for patients treated with diet and/or exercise and/or one oral hypoglycaemic agent or
- •<= 8.0% at screening for patients treated with two oral hypoglycaemic agents
- •Age ≥21 and ≤ 70 years
- •BMI ≥ 17.6 and ≤ 35 kg/m2
排除标准
- •Any finding of the medical examination including blood pressure, pulse rate and electrocardiogram (ECG) deviating from normal and of not acceptable clinical relevance
- •Clinically relevant concomitant diseases like renal insufficiency, cardiac insufficiency (NYHA II-IV), known cardiovascular diseases including hypertension (>150/95 mmHg), stroke, and transient ischemic attack (TIA).
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders, except for type 2 diabetes mellitus, hyperlipidaemia and medically treated hypertension
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders except polyneuropathy
- •Chronic or relevant acute infections (e.g., human immunodeficiency virus (HIV), hepatitis)
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug before drug administration except anti-hypertensives, acetylsalicylic acid, and statins
- •Use of drugs decreasing blood glucose within 10 days before drug administration
- •Participation in another trial with an investigational drug within two months before drug administration
- •Alcohol abuse
- •Drug abuse
- •Blood donation (100 mL or more within four weeks before drug administration)
- •Excessive physical activities (within one week before drug administration or during the trial)
- •Any laboratory value outside the reference range and the clinical relevance is not acceptable (or the value is more than three times higher than the upper limit of the normal range, e.g., liver enzymes such as aspartate aminotransferase (AST(serum glutamate oxaloacetate transaminase/ SGOT)), alanine transaminase (ALT(serum glutamate pyruvate transaminase/ SGPT)), alkaline phosphatase (γALP), and lactate dehydrogenase (LDH)
- •Fasted blood glucose >240 mg/dL (=13.3 mmol/L) on two consecutive days during washout
- •Serum creatinine above 1.3 mg/dL at screening
- •Pregnancy or child-bearing potential patients and breast-feeding patients
- •Not willing to use adequate contraception (condom use plus another form of contraception, e.g., spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole study period from the time of the first intake of study drug until one month after the last intake
研究组 & 干预措施
Low dose of BI 1356 BS
Experimental
干预措施: Low dose of BI 1356 BS (Drug)
Medium dose of BI 1356 BS
Experimental
干预措施: Medium dose of BI 1356 BS (Drug)
High dose of BI 1356 BS
Experimental
干预措施: High dose of BI 1356 BS (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of patients with adverse events
时间窗: Up to day 50
Number of patients with clinically relevant changes in vital signs (blood pressure, pulse rate)
时间窗: Up to day 50
Global assessment of tolerability by the investigator on a 4-point scale (good, satisfactory, not satisfactory and bad)
时间窗: Day 43
Number of patients with clinically relevant changes in clinical laboratory tests (haematology, clinical chemistry, and urinalysis)
时间窗: Up to day 50
次要结局
- DPP-IV activity at different time points(Up to day 43)
- Amount of the analyte that is eliminated in urine (Ae) at different time points(Up to day 43)
- Maximum measured concentration of the analyte in plasma (Cmax) at different time points(Up to day 43)
- Average concentration of the analyte in plasma at steady state (Cavg)(After the last dose on day 28 up to day 43)
- Mean residence time of the analyte in the body at steady state after oral administration (MRTpo,ss)(After last dose on day 28 up to day 43)
- Area under the concentration time curve of the analyte in plasma (AUC) at different time points(Up to day 43)
- Time from last dosing to the maximum concentration of the analyte in plasma (tmax) at different time points(Up to day 43)
- Fraction of parent drug eliminated in urine (fe) at different time points(Up to day 43)
- Renal clearance of the analyte (CLR) at different time points(Up to day 43)
- Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)(After the last dose on day 28 up to day 43)
- Terminal rate constant in plasma at steady state (λz,ss)(After last dose on day 28 up to day 43)
- Calculation of accumulation ratio of the analyte in plasma based on AUCτ (RA,AUCτ)(Up to day 43)
- Terminal half-life of the analyte in plasma at steady state (t1/2,ss)(After the last dose on day 28 up to day 43)
- Apparent clearance of the analyte in plasma at steady state after extravascular multiple dose administration (CL/F,ss)(After last dose on day 28 up to day 43)
- Apparent volume of distribution during the terminal phase λz at steady state following extravascular administration (Vz/F,ss)(After last dose on day 28 up to day 43)
- Predose concentration of the analyte in plasma (Cpre) at different time points immediately before administration of the Nth dose(Up to day 28)
- Calculation of accumulation ratio of the analyte in plasma based on Cmax (RA,Cmax)(Up to day 43)
- Minimum dipeptidyl peptidase IV (DPP-IV) activity (Emin) at different time points(Up to day 43)
- Time to reach minimum DPP-IV activity (tmin) at different time points(Up to day 43)
研究者
相似试验
已完成
3 期
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic ControlDiabetes Mellitus, Type 2NCT00621140Boehringer Ingelheim503
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male VolunteersHealthyNCT02273401Boehringer Ingelheim96
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT02183415Boehringer Ingelheim77
已完成
1 期
Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male VolunteersHealthyNCT02214901Boehringer Ingelheim91
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male VolunteersHealthyNCT02183298Boehringer Ingelheim36